Dermira (DERM) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a hold rating to a buy rating in a research note released on Thursday. They currently have $8.25 price target on the biopharmaceutical company’s stock.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
DERM has been the subject of a number of other reports. ValuEngine raised Dermira from a strong sell rating to a sell rating in a report on Tuesday, October 2nd. Cantor Fitzgerald reiterated a buy rating and set a $20.00 target price on shares of Dermira in a research report on Wednesday, November 7th. Guggenheim reiterated a buy rating and set a $20.00 target price on shares of Dermira in a research report on Tuesday, November 20th. Mizuho reiterated a hold rating and set a $10.00 target price on shares of Dermira in a research report on Tuesday, October 2nd. Finally, BidaskClub upgraded Dermira from a buy rating to a strong-buy rating in a research report on Thursday, October 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $21.04.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.63) by $0.05. The company had revenue of $0.72 million during the quarter, compared to the consensus estimate of $0.80 million. Dermira had a negative return on equity of 184.43% and a negative net margin of 496.49%. On average, equities research analysts expect that Dermira will post -5.2 EPS for the current fiscal year.
In related news, Director Matthew K. Fust sold 4,000 shares of the business’s stock in a transaction dated Friday, October 19th. The stock was sold at an average price of $13.75, for a total value of $55,000.00. Following the transaction, the director now owns 14,051 shares in the company, valued at approximately $193,201.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.80% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC increased its position in Dermira by 7.5% in the 2nd quarter. Voya Investment Management LLC now owns 1,197,773 shares of the biopharmaceutical company’s stock valued at $11,020,000 after acquiring an additional 83,064 shares during the period. Orbimed Advisors LLC acquired a new position in Dermira in the 2nd quarter valued at about $9,491,000. Dimensional Fund Advisors LP increased its position in Dermira by 48.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 920,605 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 298,677 shares during the period. Sofinnova Ventures Inc increased its position in Dermira by 35.9% in the 3rd quarter. Sofinnova Ventures Inc now owns 495,293 shares of the biopharmaceutical company’s stock valued at $5,399,000 after acquiring an additional 130,953 shares during the period. Finally, Fosun International Ltd acquired a new position in Dermira in the 3rd quarter valued at about $3,805,000. Hedge funds and other institutional investors own 84.90% of the company’s stock.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.